We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

79 hedge funds and large institutions have $351M invested in Xenon Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

13% more funds holding

Funds holding: 70 → 79 (+9)

12% more capital invested

Capital invested by funds: $314M → $351M (+$36.6M)

0.68% more ownership

Funds ownership: 79.26% → 79.95% (+0.68%)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
79
Holders Change
+9
Holders Change %
+12.86%
% of All Funds
1.62%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
20
Increased
25
Reduced
10
Closed
11
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$10.7M
2
O
OrbiMed
New York
+$10.6M
3
BBA
Baker Bros. Advisors
New York
+$10.2M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.78M
5
UBS AM
UBS AM
Illinois
+$4.64M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$22.4M
2
ACM
Aquilo Capital Management
California
-$17M
3
VC
Vivo Capital
California
-$4.5M
4
BCM
Burrage Capital Management
Massachusetts
-$2.11M
5
IC
Ikarian Capital
Texas
-$1.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
AGA
26
Altrinsic Global Advisors
Connecticut
$2.13M – – –
DMK
27
David M. Knott
$2.12M -$79K -6,204 -4%
Millennium Management
28
Millennium Management
New York
$2.11M -$325K -25,573 -13%
AS
29
Altshuler Shaham
Israel
$1.9M – – –
GPCM
30
Granite Point Capital Management
Massachusetts
$1.78M – – –
Two Sigma Investments
31
Two Sigma Investments
New York
$1.51M +$401K +31,510 +36%
GIM
32
Granahan Investment Management
Massachusetts
$1.39M – – –
Two Sigma Advisers
33
Two Sigma Advisers
New York
$1.26M +$476K +37,400 +59%
JP Morgan Chase
34
JP Morgan Chase
New York
$1.21M +$589K +46,253 +92%
Vanguard Group
35
Vanguard Group
Pennsylvania
$1.19M +$1.21M +94,743 New
State Street
36
State Street
Massachusetts
$1.09M +$861K +67,686 +357%
Marshall Wace
37
Marshall Wace
United Kingdom
$1.04M +$1.06M +82,912 New
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$979K +$360K +28,252 +57%
BlackRock
39
BlackRock
New York
$866K +$782K +61,436 +797%
Swiss National Bank
40
Swiss National Bank
Switzerland
$784K +$795K +62,500 New
Northern Trust
41
Northern Trust
Illinois
$772K +$38.6K +3,036 +5%
Acadian Asset Management
42
Acadian Asset Management
Massachusetts
$762K +$703K +55,244 +972%
AA
43
ALPS Advisors
Colorado
$598K +$607K +47,704 New
PNC Financial Services Group
44
PNC Financial Services Group
Pennsylvania
$573K – – –
BFM
45
Boothbay Fund Management
New York
$560K -$258K -20,304 -31%
SC
46
Scotia Capital
Ontario, Canada
$522K +$267 +21 +0.1%
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$512K -$2.39K -188 -0.5%
SSA
48
Schonfeld Strategic Advisors
New York
$447K +$288K +22,600 +174%
MWNA
49
Marshall Wace North America
New York
$389K +$78.8K +6,194 +25%
Deutsche Bank
50
Deutsche Bank
Germany
$382K -$822K -64,611 -68%
1
2
3 4

XENE Hedge Fund Activity: Q2 2020 in Review

79 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2020, worth a combined $351M — up 12% from $314M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new XENE positions and 11 closed out — a net gain of 9 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was BVF Inc, adding an estimated $10.7M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $22.4M sold.

  • 79 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2020, up from 70 in Q1 2020.
  • Funds reported $351M of Xenon Pharmaceuticals stock for Q2 2020, up 12% quarter-over-quarter.
  • 20 funds opened new Xenon Pharmaceuticals positions in Q2 2020 and 11 closed out, a net change of +9 holders.
  • The largest Xenon Pharmaceuticals buyer in Q2 2020 was BVF Inc, an estimated $10.7M added.
  • The largest Xenon Pharmaceuticals seller in Q2 2020 was Consonance Capital Management, an estimated $22.4M sold.

Based on aggregated 13F filings for Q2 2020.